Strategic Expansion

LABOPHAR is undertaking a strategic expansion to enhance our manufacturing capabilities and product offerings.

New Manufacturing Facility

LABOPHAR is establishing a new manufacturing facility for intravenous (IV) fluids, syrups and topicals products in Rwanda.

The facility will meet current Good Manufacturing Practice (GMP) and global regulatory requirements, ensuring the highest quality standards for all our products.

This expansion will significantly enhance our production capacity and enable us to better serve healthcare facilities throughout Rwanda and neighboring countries.

New Product Lines

Our expansion will enable us to manufacture several new product lines to meet the growing healthcare needs in Rwanda and Africa.

IV Fluids

Sterile intravenous solutions for fluid replacement therapy, including normal saline, dextrose, and Ringer's lactate.

Syrups

Liquid medication formulations including cough syrups, antihistamines, and multivitamin supplements.

Topicals

Topical medications for skin conditions, including antibiotic ointments, anti-inflammatory creams, and moisturizing products.

Benefits of Our Expansion

Increased availability of essential medications in Rwanda and neighboring countries
Reduced dependence on imported pharmaceutical products
Creation of new employment opportunities for skilled workers
Enhanced healthcare infrastructure in the region
Contribution to Rwanda's economic development and healthcare self-sufficiency